This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Felice, M. Articles by Di Lauro, R. Search for Related Content PubMed PubMed Citation Articles by De Felice, M. Articles by Di Lauro, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Medline Plus Health Information Thyroid Diseases

Minireview: Thyrotropin Receptor Signaling in Development and Differentiation of the Thyroid Gland: Insights from Mouse Models and Human Diseases

Stazione Zoologica Anton Dohrn (M.D.F., M.P.P., R.D.L.) and Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II (R.D.L.), Naples 80121, Italy

Address all correspondence and requests for reprints to: Dr. Roberto Di Lauro, Stazione Zoologica Anton Dohrn, Naples 80121, Italy. E-mail: rdilauro{at}unina.it.

IN 1927, UHLENHUTH (1) demonstrated that the anterior lobe of the pituitary gland of salamanders produces a factor capable of controlling the function of the thyroid. This factor was subsequently called TSH. Forty years later, Pastan and co-workers (2) demonstrated that TSH exerts its effects through a protease-sensitive structure on the thyroid cell plasma membrane, thus postulating the existence of a specific receptor (TSH-R; the current official name is Tshr for mouse genetic locus and TSHR for the human locus). The relevance of the interaction between TSH and its receptor in the physiology and pathology of the thyroid became immediately clear, and indeed in 1968 Stanbury (3) suggested that congenital hypothyroidism in the absence of goiter could be due to an impaired response to TSH.

The mechanisms triggered by Tshr upon interaction with the ligand, which regulate both proliferation and function of thyroid cells, have been exhaustively studied mainly in cell culture models. Several comprehensive reviews summarize these aspects of TSH signaling (4, 5, 6, 7, 8). This review will focus on a different aspect of TSH signaling, its role in the development and differentiation of the thyroid, as determined by the study of alterations in this pathway in both mice and humans. Indeed, these studies have provided important insights about the physiological roles of TSH/Tshr signaling, in some cases underscoring the pivotal role that this system plays in regulating the size and function of the thyroid gland; in others demoting it to, at best, a marginal modulator. Furthermore, the animal models have been useful in discovering new important functions of such signaling systems in extrathyroidal tissues (9), which are beyond the scope of this review.

Animal models with impaired TSH/Tshr signaling

Several mutant mouse lines that lack either a functional Tshr or TSH have been reported and described. Tshr^hyt/Tshr^hyt (formerly hyt/hyt) mice (10) are spontaneous mutant mice characterized by hypothyroidism and failure to respond to TSH. These mice have a point mutation in the coding region of the Tshr gene (11) that causes the replacement of a highly conserved proline (Pro⁵⁵⁶) in transmembrane domain IV with a leucine. This mutation leads to a defective binding with TSH (12). More recently, a mouse model in which the Tshr gene has been inactivated by homologous recombination in embryonic stem cells has been generated (13). As expected, both of these mouse types display hypothyroidism with thyroid hypoplasia.

Another model of impaired TSH signaling is the pit^dw/pit^dw (formerly Snell dwarf or dw/dw) mouse (14). These hypothyroid mice carry a loss of function mutation in the sequence encoding the POU domain of the transcription factor Pit1. Mice homozygous for this mutation do not express TSH, GH, or prolactin (15). Furthermore, a mouse was generated in which the gene encoding the -glycoprotein hormone subunit (-GSU) had been disrupted (16). The -subunit is common to the pituitary hormones TSH, LH, and FSH. As a consequence, -GSU-null mice are hypothyroid and hypogonadal.

It is important to stress that mice with mutations resulting in loss of the TSH receptor have a thyroid phenotype comparable with that of mice with mutations knocking out TSH. Small differences observed in the phenotype could be due to the diverse genetic background of the mice. This observation suggests that the constitutive activity of the receptor alone (17) is not sufficient to maintain the level of a physiological response in vivo. In addition, the thyroid phenotype of mutants in the TSH/Tshr pathway is not worsened by the absence of additional hormones as in the case of the pit^dw /pit^dw or -GSU-null mice. This observation allows us to conclude that other pituitary hormones have no supplementary effect, either direct or indirect, on thyroid function.

The early steps of thyroid differentiation are independent of Tshr signaling

The expression of Tshr during thyroid morphogenesis in mammals has been mainly analyzed in rodents. Tshr mRNA is barely detected in the embryonic thyroid of mice and rats on embryonic d 14 (E14) (our unpublished observations; Fig. 1) and E15, respectively (18, 19). The level of expression increases on subsequent days of fetal life. The Pit1-dependent expression of TSHß in the caudomedial cells of the pituitary begins on E15.5 (20), whereas -GSU mRNA is expressed in the mouse pituitary from E12.5 (21). Information about expression during human development is more limited. The onset of TSHR expression in humans has not yet been reported. TSH is detectable in the pituitary (22) and serum (23) at approximately 12 wk gestation, and its levels increase during the second trimester of gestation (24).

View larger version (50K): [in this window] [in a new window]   FIG. 1. Onset of functional differentiation in mouse developing thyroid. A, Serial sagittal sections on E14 (A–D) and E15 (E–H) were hybridized with the indicated antisense probe. B, Serial sagittal sections on E14 (A and B) and E16 (C and D) were stained with the indicated antibodies. Tshr mRNA is first barely detected in the embryo thyroid on E14 and coincides with that of TPO. NIS expression begins on E16. [Reprinted from Postiglione et al. (35 ).]

Activation of the TSH/Tshr pathway in the developing thyroid is coincident with the onset of thyroid hormone (TH) biosynthesis, and, therefore, it could be an important trigger for the expression of genes such as thyroglobulin (Tg), thyroid peroxidase (TPO), and sodium-iodide symporter (NIS) that encode proteins belonging to TH biosynthetic machinery. Because the expression of Tg, TPO, and NIS genes depends (at least in part) on the presence of the transcription factors Titf1, Pax8, and Foxe1 (27), it is plausible that the TSH/Tshr pathway acts through these transcription factors. In support of this view, several reports have shown that in vitro the TSH/Tshr pathway can regulate the expression of Titf1, Pax8, and Foxe1.

Rat thyroid cells cultured in the absence of TSH express the transcription factor Titf1. This expression is down-regulated by the addition of either TSH or forskolin (28). This TSH-dependent down-regulation of Titf1 is due to a decrease in the transcription rate from the Titf1 promoter (29). However, in primary cultures of dog thyrocytes, there is no significant variation in the levels of Titf1 mRNA and protein in response to cAMP agonists (30). This discrepancy can be attributed to the differences between the two systems used (primary cultures vs. continuous cell line) or to species-specific differences in Titf1 gene regulation. Unlike Titf1, the steady state levels of Pax8 mRNA and protein are clearly increased after the addition of forskolin in both rat thyroid cells (29) and primary cultured dog thyrocytes (31). Foxe1 was identified as a thyroid-specific nuclear factor induced by TSH and forskolin (32). The transcription of Foxe1 strictly depends on the presence of either TSH or IGF-I or high doses of insulin in thyroid cells in culture (25, 33). The hormonal induction of Foxe1 mRNA levels required ongoing protein synthesis (33). However, in primary cultures of dog thyrocytes, the DNA-binding activity of Foxe1 is clearly detectable even in the absence of TSH stimulation (34).

A detailed analysis of the gene expression pattern in the developing thyroid of the mutant mice described above has recently been reported (35) and has shown a rather different picture. Indeed, using this in vivo approach, it has been demonstrated that the absence of a functional Tshr or its ligand does not affect the expression of Titf1, Pax8, and Foxe1. Even in pit^dw/pit^dw mice, which lack TSH, GH and, as consequence of this, IGF-I, the expression of thyroid-enriched transcription factors is comparable to that in wild-type mice. These data strongly suggest that, at least during fetal life, the expression of Titf1, Pax8, and Foxe1 is not strictly dependent on TSH or IGF-I. However, it is still conceivable that these hormones regulate the expression of these transcription factors in vivo, but in their absence, another hormone or growth factor could trigger their transcription.

Tshr signaling and functional differentiation of thyroid cells

In the developing thyroid, after the induction of Tshr, the expression of NIS begins (35) and the levels of both Tg and TPO increase (19). These observations are in agreement with several reports demonstrating, in different systems, that TSH/Tshr signaling positively regulates the synthesis of genes essential for thyroid physiology, such as NIS, TPO, and Tg.

NIS and TPO.

TSH stimulates iodide accumulation in rat thyroid cells through a cAMP-dependent mechanism (36). The TSH/Tshr pathway is involved in regulating the expression and activity of NIS at different levels: TSH up-regulates NIS protein in the rat thyroid (37) and the mRNA in rat thyroid cells (38). The TSH-induced stimulation of NIS expression requires protein synthesis (38). In rats, an enhancer that recapitulates the most relevant aspects of NIS regulation has been identified (39). A strong increase in the expression of NIS mRNA has been reported in dog thyroid and human thyroid primary cultures after goitrogenic treatment (40, 41, 42). In addition to the regulation of NIS transcription and biosynthesis, TSH/Tshr signaling is also required to target NIS to the plasma membrane (43). The phosphorylation of specific residues dependent on the presence of TSH might be involved in regulation of the subcellular distribution of NIS (43).

The regulation of TPO by TSH is mostly at the mRNA level. In dog thyroid primary cultures, TSH or cAMP agonist induces TPO mRNA accumulation by an increase in the gene transcription rate. This effect is rapid and does not require protein synthesis, suggesting that the TPO promoter can be directly controlled via cAMP regulatory elements (44, 45). On the contrary, in rat thyroid cells in culture, TSH has been shown to increase the steady state TPO mRNA level (46, 47) by indirect mechanisms. Regulatory sequences responsive to TSH and cAMP signals have been identified at the 5'-flanking region in functional studies of both human (48) and rat (32) TPO promoters.

Animal models deficient in TSH/Tshr signaling are an excellent tool to confirm the importance of TSH in the control of NIS and TPO expression in the whole organism. In Tshr^hyt/Tshr^hyt, Tshr-null, and pit^dw/pit^dw mice, the expression of some thyroid-specific genes has been carefully analyzed at the end of thyroid organogenesis (35) and in adult life (13). NIS and TPO are almost undetectable in mutant thyroids on E17 (Fig. 2). The same result was observed in the thyroids of adult Tshr-null mice, which fail to express the NIS protein.

View larger version (115K): [in this window] [in a new window]   FIG. 2. TSH signals control the expression of NIS and TPO in mouse developing thyroid gland. Wild-type (A–C), Tshrhyt/Tshrhyt (D–F), pit1dw/pit1dw (G–I), and TSHR-KO (J–L) E17.5 embryos were stained with anti-Tg (A, D, G, and J), and anti-NIS (B, E, H, and K), or hybridized with TPO antisense probe (C, F, I, and L). In the absence of functioning TSH/Tshr signaling, the expression of both NIS and TPO was almost abolished, whereas Tg appears only slightly decreased. [Reprinted from Postiglione et al. (35 ).]

Tg.

The influence of TSH on Tg has been known for many years (54). The role of TSH signals in Tg expression has been extensively investigated in different systems, and there is a general consensus that TSH increases the level of Tg mRNA and that cAMP is the physiological mediator of this effect (55, 56). Interestingly, the extent of this regulation is variable in these different reports. In rat (57, 58) and porcine (59) thyroid cells, TSH approximately doubles the rate of transcription of Tg. In hypophysectomized rats (60), TSH control seems to be tighter. However, recent experiments in mice carrying loss of function mutations in Tshr suggest that Tsh/Tshr signaling has a moderate effect on Tg expression in vivo (see below). The increase in Tg mRNA transcription in response to TSH or a cAMP agonist is slow. Furthermore, cycloheximide inhibits the increase in Tg expression (44), indicating that TSH induction requires newly synthesized proteins. These data suggest that TSH uses different mechanisms to control TPO and Tg synthesis (44, 46, 61). The effect of TSH on the Tg promoter is not direct, as observed for the TPO promoter, but is mediated by other factors that are the primary targets of cAMP induction (44, 61). Consistent with these data is the fact that no canonical cAMP response elements have been identified in the 5' region of the gene. The mediators of the TSH signal on the Tg promoter are still unknown. Pax8 has been hypothesized to be a link between the TSH pathway and Tg transcription. However, it has been shown that Pax8 alone is not sufficient to reactivate the expression of Tg in the absence of TSH stimulation (62).

The expression of Tg has been studied in the animal models described above at the end of thyroid organogenesis (35) and in adult mice (13). Unlike both NIS and TPO, which are absent in E17 mutant thyroid, Tg appears to be only slightly decreased in mutant mice compared with wild-type animals. Also in the adult mutant, the expression of Tg is only barely affected. These studies in animal models might be consistent with data obtained from patients with inactive TSHR that present relatively normal circulating Tg levels. In addition, no increased Tg mRNA has been reported in either Graves’ disease or toxic adenomas (52, 53).

In conclusion, the studies that we have summarized allow us to state two important concepts. The first is that there is not a tight control of TSH over Tg expression, and thus TSH is not the major regulator of Tg transcription. The second is that the known role of Tshr signaling in Tg iodination is based, besides the well established activation of H₂O₂ generation (63, 64), on the coordinated and tight control of NIS and TPO expression. It should be of great interest to discover whether other players of this pathway are also under TSH control.

Tshr and thyroid cells proliferation

The developing thyroid begins to expand significantly in size only after the end of migration from the pharyngeal cavity, at the same stage at which follicular cells begin to synthesize TH. By E15–16 in mice and E70 in humans, the gland exhibits its definitive shape, two lobes connected by a narrow isthmus. It is worth noting that the onset of this expansion coincides with the appearance of TSH in serum.

The growth of the thyroid continues after birth. In mice, the weight of the thyroid increases during the first month of life (65). In humans, the growth of the thyroid roughly parallels body growth during childhood (66). At the adult stage, the estimated turnover time for follicular cells, using in vitro labeling experiments, is approximately 8.5 yr (67).

TSH, mainly using cAMP as a second messenger, induces cell proliferation in rat thyroid cell lines and primary cultures of thyrocytes from different species. However, studies of different models demonstrated that in the thyroid other distinct mitogenic cascades are present and promote cell proliferation. The most relevant ones are the pathways stimulated by growth factors such as IGF-I or epidermal growth factor. Furthermore, a third cascade, the phospholipase C cascade, induced by tumor-promoting phorbol esters or ₁-adrenergic agonist, has been shown to enhance the proliferation and dedifferentiation of thyroid cells (4).

In all systems, TSH is the main regulator of thyroid growth, whereas IGF-I (or insulin at supraphysiological concentrations) is required for the mitogenic action of TSH (4). Indeed, IGF-I/insulin alone does stimulate the proliferation of either dog or human thyroid cells in primary culture, whereas rat thyroid cell lines can weakly proliferate in response to IGF-I/insulin alone (4). These data have been confirmed in vivo by the comparison of the thyroid phenotype of two transgenic mice, one overexpressing in thyroid the A₂ adenosine receptor (68), which causes constitutive activation of adenylyl cyclase, and the other characterized by simultaneous overexpression in the gland of IGF-I and its receptor (69). In adult A₂ adenosine receptor transgenic mice, the dramatic enlargement of the gland, whose weight increases more than 100 times, is due to strong hyperplasia of the thyroid. Indeed, bromodeoxyuridine incorporation reveals that the proliferation of thyroid cells continues throughout life. On the contrary, transgenic mice overexpressing IGF-I/IGF-I receptor show mild enlargement of the thyroid as a consequence of hypertrophy of the gland without an increase in the cell population. The gland displays an increased follicular lumen area and a slight decrease in the number of cells per square millimeter compared with the wild-type thyroid. In humans, IGF-I has little mitogenic effect; actually patients with acromegaly display enlarged thyroids (70). However, IGF-I signaling in humans in vivo seems to be required for the mitogenic action of TSH, as demonstrated by the low endemic goiter prevalence among pygmies (71).

In support of the fact that TSH/Tshr signaling per se has a relevant role in thyroid growth in adults is the thyroid phenotype displayed by all animal models carrying natural or induced mutations in Tshr or its cognate ligand (13, 14, 16, 72). All mutants are hypothyroid and show a hypoplastic adult thyroid characterized by small sparse follicles, areas not organized into follicles, and a reduced number of cells. Although these data confirm the mitogenic effect of the TSH-induced cAMP pathway in the adult thyroid, the growth control of the fetal thyroid is still puzzling.

Pioneering works (reviewed in Ref. 73), reported that the thyroid develops in decapitated rabbit fetus or in hypophysectomized chick embryo. More recently, it has been reported that the size of the thyroid in both Tshr^hyt/Tshr^hyt and pit^dw/pit^dw mice on E17 is similar to that in wild-type mice (35). Furthermore, the number of proliferating cells in the thyroid is comparable in mutants and wild-type embryos. In addition, the morphology of mutant thyroids is not affected by the absence of a functional Tshr, indicating that folliculogenesis is correctly initiated. Although these data do not exclude a role for TSH in controlling the growth of the embryonic thyroid, they suggest that in thyroid gland development the proliferation of thyrocytes could be controlled by a cAMP-independent mechanism. Consistent with this scenario is the observation that in A₂ adenosine receptor transgenic mice (68) (see above), the morphology of the thyroid at birth is comparable to that in wild-type newborn mice.

These data raise the question of what might regulate the expansion of thyroid cells in the developing thyroid. At the moment, we can only suggest some hypotheses.

Epidermal growth factor, acting through its tyrosine kinase receptor, has been demonstrated to promote the proliferation of rat and dog thyroid cells in culture. This factor (74) and its receptor (75) are both expressed in the thyroid, thus suggesting that a potential autocrine/paracrine tyrosine kinase-dependent regulation could be involved in controlling the growth of the thyroid during fetal life in vivo. Another candidate regulator could be a member of the fibroblast growth factor (Fgf) family. Basic Fgf has been reported to induce DNA synthesis in thyroid cells in culture. An isoform of the Fgf receptor, Fgfr2, has been detected in the developing thyroid (76). This finding suggests that thyroid precursor cells are competent to respond to Fgf10 present in the surrounding mesenchyme, which has critical mitogenic activity in other organs, such as the developing pituitary and pancreas.

In in vitro models, only TSH/cAMP signals are able to trigger proliferation and differentiation programs, whereas the other pathways induce proliferation and repress differentiation. This observation could explain why TSH/cAMP signals are indispensable in a fully functional thyroid (i.e. in postnatal life), whereas they can be replaced by other signals during development.

In human, thyroid organogenesis is complete by 12–13 wk, but the gland continues to grow until term. In addition, the functions of the hypothalamic-pituitary-thyroid axis are accomplished in humans at midgestation (24), but only after birth in rodents. This suggests that the data from the mouse models cannot be directly extrapolated to the human. The mechanisms controlling the growth of fetal thyroid could be (unexpectedly) different in the different species.

In conclusion, recent data agree with the old concept that TSH/TSHR signaling is essential for thyroid function. However, as far as gene expression is concerned, only a subset of the genes involved in TH biosynthesis is tightly controlled by TSH, thus indicating that there is no coordinate control of the entire thyroid differentiation program. Furthermore, thyroid gland size seems to be differentially controlled during embryonal life (by an unknown mechanism) and in the adult (by TSH). Whether these last features are identical in mice and humans remain to be ascertained.

Acknowledgments

We thank Prof. J. Dumont for critical comments on the manuscript.

Footnotes

This work was supported in part by Telethon, "Congenital Hypothyroidism with Thyroid Dysgenesis: Candidate Genes, Animal Models and Molecular Mechanisms;" Associazione Italiana per la Ricerca sul Cancro "Identification of Ras Oncogene Sequences and Effectors Responsible for Inducing De-Differentiation in Epithelial Cells;" and Ministero dell’Università e della Ricerca Scientifica e Tecnologica, "I Geni dell’Uomo," cluster 01.

Abbreviations: E, Embryonic day; Fgf, fibroblast growth factor; -GSU, -glycoprotein hormone subunit; NIS, sodium-iodide symporter; Tg, thyroglobulin; TH, thyroid hormone; TPO, thyroid peroxidase; TSH-R, TSH receptor.

Received April 19, 2004.

Accepted for publication June 4, 2004.

References

1. Uhlenhuth E, Schwartzbach S 1927 The anterior lobe of the hypophsis as a control mechanism of the function of the thyroid gland. Br J Exp Biol 5:1–5
2. Pastan I, Roth J, Macchia V 1966 Binding of hormone to tissue: the first step in polypeptidehormone action. Proc Natl Acad Sci USA 56:1802–1809[Free Full Text]
3. Stanbury JB, Rocmans P, Buhler UK, Ochi Y 1968 Congenital hypothyroidism with impaired thyroid response to thyrotropin. N Engl J Med 279:1132–1136
4. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger P 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22:631–656[Abstract/Free Full Text]
5. Davies T, Marians R, Latif R 2002 The TSH receptor reveals itself. J Clin Invest 110:161–164[CrossRef][Medline]
6. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD 2002 Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82:473–502[Abstract/Free Full Text]
7. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM 1998 The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 19:673–716[Abstract/Free Full Text]
8. Vassart G, Dumont J 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 13:596–611[CrossRef][Medline]
9. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M 2003 TSH is a negative regulator of skeletal remodeling. Cell 115:151–162[CrossRef][Medline]
10. Beamer WJ, Eicher EM, Maltais LJ, Southard JL 1981 Inherited primary hypothyroidism in mice. Science 212:61–63[Abstract/Free Full Text]
11. Stuart A, Oates E, Hall C, Grumbles R, Fernandez L, Taylor N, Puett D, Jin S 1994 Identification of a point mutation in the thyrotropin receptor of the hyt/hyt hypothyroid mouse. Mol Endocrinol 8:129–138[Abstract]
12. Gu WX, Du GG, Kopp P, Rentoumis A, Albanese C, Kohn LD, Madison LD, Jameson JL 1995 The thyrotropin (TSH) receptor transmembrane domain mutation (Pro⁵⁵⁶-Leu) in the hypothyroid hyt/hyt mouse results in plasma membrane targeting but defective TSH binding. Endocrinology 136:3146–3153[Abstract]
13. Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF 2002 Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci USA 99:15776–15781[Abstract/Free Full Text]
14. Cordier AC, Denef JF, Haumont S 1976 Thyroid gland in dwarf mice. Cell Tissue Res 171:449–475[Medline]
15. Li S, Crenshaw EBI, Rawson EJ, DM S, Swanson LW, Rosenfeld M 1990 Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 347:528–533[CrossRef][Medline]
16. Kendall SK, Samuelson LC, Saunders TL, Wood RI, Camper SA 1995 Targeted disruption of the pituitary glycoprotein hormone -subunit produces hypogonadal and hypothyroid mice. Genes Dev 9:2007–2019[Abstract/Free Full Text]
17. Cetani F, Tonacchera M, Vassart G 1996 Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett 378:27–31[CrossRef][Medline]
18. Lazzaro D, Price M, De Felice M, Di Lauro R 1991 The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 113:1093–1104[Abstract]
19. Brown RS, Shalhoub V, Coulter S, Alex S, Joris I, De Vito W, Lian J, Stein GS 2000 Developmental regulation of thyrotropin receptor gene expression in the fetal and neonatal rat thyroid: relation to thyroid morphology and to thyroid-specific gene expression. Endocrinology 141:340–345[Abstract/Free Full Text]
20. Lin SC, Li S, Drolet DW, Rosenfeld MG 1994 Pituitary ontogeny of the Snell dwarf mouse reveals Pit-1-independent and Pit-1-dependent origins of the thyrotrop. Development 120:515–522[Abstract]
21. Japon MA, Rubinstein M, Low MJ 1994 In situ hybridization analysis of anterior pituitary hormone gene expression during fetal mouse development. J Histochem Cytochem 42:1117–1125[Abstract]
22. Puy LA, Asa S 1996 The ontogeny of pit-1 expression in the human fetal pituitary gland. Neuroendocrinology 63:349–355[Medline]
23. Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J, McGregor A 1991 Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med 324:532–536[Abstract]
24. Fisher DA, Klein A 1981 Thyroid development and disorders of thyroid function in the newborn. N Engl J Med 304:702–712[Medline]
25. Zannini M, Avantaggiato V, Biffali E, Arnone M, Sato K, Pischetola M, Taylor B A, Phillips S J, Simeone A, Di Lauro R 1997 TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. EMBO J 16:3185–3197[CrossRef][Medline]
26. Thomas PQ, Brown A, Beddington R 1998 Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early transient marker of endothelial cell precursors. Development 125:85–95[Abstract]
27. Damante G, Tell G, Di Lauro R 2001 A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acids Res Mol Biol 66:307–356[Medline]
28. Saito T, Endo T, Nakazato M, Kogai T, Onaya T 1997 Thyroid-stimulating hormone-induced down-regulation of thyroid transcription factor 1 in rat thyroid FRTL-5 cells. Endocrinology 138:602–606[Abstract/Free Full Text]
29. Medina DL, Suzuki K, Pietrarelli M, Okajima F, Kohn LD, Santisteban P 2000 Role of insulin and serum on thyrotropin regulation of thyroid transcription factor-1 and pax-8 genes expression in FRTL-5 thyroid cells. Thyroid 10:295–303[Medline]
30. Van Renterghem P, Dremier S, Vassart G, Christophe D 1995 Study of TTF-1 gene expression in dog thyrocytes in primary culture. Mol Cell Endocrinol 112:83–93[CrossRef][Medline]
31. Van Renterghem P, Vassart G, Christophe D 1996 Pax 8 expression in primary cultured dog thyrocyte is increased by cyclic AMP. Biochim Biophys Acta 1307:97–103[Medline]
32. Aza-Blanc P, Di Lauro R, Santisteban P 1993 Identification of a cis-regulatory element and a thyroid-specific nuclear factor mediating the hormonal regulation of rat thyroid peroxidase promoter activity. Mol Endocrinol 7:1297–1306[Abstract]
33. Ortiz L, Zannini MS, Di Lauro R, Santisteban P 1997 Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin and insulin-like growth factor 1. J Biol Chem 272:23334–23339[Abstract/Free Full Text]
34. Pouillon V, Pichon B, Donda A, Christophe D 1998 TTF-2 does not appear to be a key mediator of the effect of cyclic AMP on thyroglobulin gene transcription in primary cultured dog thyrocytes. Biochem Biophys Res Commun 242:327–331[CrossRef][Medline]
35. Postiglione MP, Parlato R, Rodriguez-Mallon A, Rosica A, Mithbaokar P, Maresca M, Marians RC, Davies TF, Zannini MS, De Felice M, Di Lauro R 2002 Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. Proc Natl Acad Sci USA 99:15462–15467[Abstract/Free Full Text]
36. Weiss SJ, Philp NJ, Ambesi-Impiombato FS, Grollman EF 1984 Thyrotropin-stimulated iodide transport mediated by adenosine 3',5'-monophosphate and dependent on protein synthesis. Endocrinology 114:1099–1107[Abstract]
37. Levy O, Dai G, Riedel, Paul EM, Lebowitz AN, Carrasco N 1997 Characterization of the thyroid Na⁺/I symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA 94:5568–55573[Abstract/Free Full Text]
38. Kogai T, Endo T, Saito T, Miyakazi A, Kawaguchi A, Onaya T 1997 Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138:2227–2232[Abstract/Free Full Text]
39. Ohno M, Zannini MS, Levy O, Carrasco N, Di Lauro R 1999 The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 19:2051–2060[Abstract/Free Full Text]
40. Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont JE, Miot F 1997 Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na⁺/I^– symporter mRNAs in dog thyroid. Mol Cell Endocrinol 131:195–203[CrossRef][Medline]
41. Saito T, Endo T, Kawaguchi A, Ikeda M, Nakazato M, Kogai T, Onaya T 1997 Increased expression of the Na⁺/I^– symporter in cultured human thyroid cells exposed to thyrotropin and in Graves’ thyroid tissue. J Clin Endocrinol Metab 82:3331–3336[Abstract/Free Full Text]
42. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM 2000 Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167:125–135[Abstract]
43. Riedel C, Levy O, Carrasco N 2001 Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276:21458–21463[Abstract/Free Full Text]
44. Gerard CM, Lefort A, Libert F, Christophe D, Dumont JE, Vassart G 1988 Transcriptional regulation of the thyroperoxydase gene by thyrotropin and forskolin. Mol Cell Endocrinol 60:239–242[CrossRef][Medline]
45. Pohl V, Abramowicz M, Vassart G, Dumont JE, Roger PP 1993 Thyroperoxidase mRNA in quiescent and proliferating thyroid epithelial cells: expression and subcellular localization studied by in situ hybridization. Eur J Cell Biol 62:94–104[Medline]
46. Isozaki O, Kohn LD, Kozak CA, Kimura S 1989 Thyroid peroxidase: rat cDNA sequence, chromosomal localization in mouse, and regulation of gene expression by comparison to thyroglobulin in rat FRTL-5 cells. Mol Endocrinol 3:1681–1692[CrossRef][Medline]
47. Damante G, Chazenbalk G, Russo D, Rapoport B, Foti D, Filetti S 1989 Thyrotropin regulation of thyroid peroxidase messenger ribonucleic acid levels in cultured rat thyroid cells: evidence for the involvement of a nontranscriptional mechanism. Endocrinology 124:2889–2894[Abstract]
48. Abramowicz MJ, Vassart G, Christophe D 1992 Functional study of the human thyroid peroxidase gene promoter. Eur J Biochem 203:467–473[Medline]
49. Abramowicz MJ, Duprez L, Parma J, Vassart G, Heinrichs C 1997 Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 99:3018–3024[Medline]
50. Bretones P, Duprez L, Parma J, David M, Vassart G, Rodien P 2001 A familial case of congenital hypothyroidism caused by a homozygous mutation of the thyrotropin receptor gene. Thyroid 11:977–980[CrossRef][Medline]
51. Gagne N, Parma J, Deal C, Vassart G, Van Vliet G 1998 Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? J Clin Endocrinol Metab 83:1771–1775[Abstract/Free Full Text]
52. Deleu S, Allory Y, Radulescu A, Pirson I, Carrasco N, Corvilain B, Salmon I, Franc B, Dumont JE, Van Sande J, Maenhaut C 2000 Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10:131–140[Medline]
53. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberge M 1999 Expression of the Na⁺/I^– symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228–3234[Abstract/Free Full Text]
54. Chebath J, Chabaud O, Mauchamp J 1979 Modulation of thyroglobulin messenger RNA level by thyrotropin in cultured thyroid cells. Nucleic Acids Res 25:3353–3367
55. Roger PP, Hotimsky A, Moreau C, Dumont JE 1982 Stimulation by thyrotropin, cholera toxin and dibutyryl cyclic AMP of the multiplication of differentiated thyroid cells in vitro. Mol Cell Endocrinol 26:165–176[CrossRef][Medline]
56. Van Heuverswyn B, Leriche A, Van Sande J, Dumont JE, Vassart G 1985 Transcriptional control of thyroglobulin gene expression by cyclic AMP. FEBS Lett 188:192–196[CrossRef][Medline]
57. Avvedimento VE, Tramontano D, Ursini MV, Monticelli A, Di Lauro R 1984 The level of thyroglobulin mRNA is regulated by TSH both in vitro and in vivo. Biochem Biophys Res Commun 122:472–477[CrossRef][Medline]
58. Santisteban P, Kohn LD, Di Lauro R 1987 Thyroglobulin gene expression is regulated by insulin and insulin-like growth factor I, as well as thyrotropin, in FRTL-5 thyroid cells. J Biol Chem 262:4048–4052[Abstract/Free Full Text]
59. Chabaud O, Chambard M, Gaudry N, Mauchamp J 1988 Thyrotrophin and cyclic AMP regulation of thyroglobulin gene expression in cultured porcine thyroid cells. J Endocrinol 116:25–33[Abstract/Free Full Text]
60. Van Heuverswyn B, Streydio C, Brocas H, Refetoff S, Dumont J, Vassart G 1984 Thyrotropin controls transcription of the thyroglobulin gene. Proc Natl Acad Sci USA 81:5941–5945[Abstract/Free Full Text]
61. Lee NT, Nayfeh SN, Chae CB 1989 Induction of nuclear protein factors specific for hormone-responsive region during activation of thyroglobulin gene by thyrotropin in rat thyroid FRTL-5 cells. J Biol Chem 264:7523–7530[Abstract/Free Full Text]
62. Mascia A, Nitsch L, Di Lauro R, Zannini M 2002 Hormonal control of the transcription factor Pax8 and its role in the regulation of thyroglobulin gene expression in thyroid cells. J Endocrinol 172:163–176[Abstract]
63. Raspe E, Dumont JE 1994 Control of the dog thyrocyte plasma membrane iodide permeability by the Ca²⁺-phosphatidylinositol and adenosine 3',5'-monophosphate cascades. Endocrinology 135:986–995[Abstract]
64. Raspe E, Laurent E, Corvilain B, Verjans B, Erneux C, Dumont J 1991 Control of the intracellular Ca²⁺-concentration and the inositol phosphate accumulation in dog thyrocyte primary culture: evidence for different kinetics of Ca²⁺-phosphatidylinositol cascade activation and for involvement in the regulation of H₂O₂ production. J Cell Physiol 146:242–250[CrossRef][Medline]
65. Modric T, Rajkumar K, Murphy LJ 1999 Thyroid gland function and growth in IGF binding protein-1 transgenic mice. Eur J Endocrinol 149–159
66. Fisher D 1986 Thyroid physiology in the perinatal period and during childhood. In: Ingbar SI, Braverman LE, eds The thyroid. Philadelphia: Lippincott; 1387–1395
67. Coclet J, Foureau F, Ketelbant P, Galand P, Dumont JE 1989 Cell population kinetics in dog and human adult thyroid. Clin Endocrinol (Oxf) 31:655–665[Medline]
68. Ledent C, Dumont JE, Vassart G, Parmentier M 1992 Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J 11:537–542[Medline]
69. Clement S, Refetoff S, Robaye B, Dumont JE, Schurmans S 2001 Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology 142:5131–5139[Abstract/Free Full Text]
70. Cheung NW, Lou JC, Boyages SC 1996 Growth hormone does not increase thyroid size in the absence of thyrotropin: a study in adults with hypopituitarism. J Clin Endocrinol Metab 81:1179–1183[Abstract]
71. Dormitzer PR, Ellison PT, Bode HH 1989 Anomalously low endemic goiter prevalence among Efe pygmies. Am J Phys Anthropol 78:527–531[CrossRef][Medline]
72. Beamer WG, Cresswell L 1982 Defective thyroid ontogenesis in fetal hypothyroid (hyt/hyt) mice. Anat Rec 202:387–393[CrossRef][Medline]
73. Dumont JE, Lamy F, Roger P, Maenhaut C 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 72:667–697[Free Full Text]
74. Kajikawa K, Yasui W, Sumiyoshi H, Yoshida K, Nakayama H, Ayhan A, Yokozaki H, Ito H, Tahara E 1991 Expression of epidermal growth factor in human tissues. Immunohistochemical and biochemical analysis. Virchows Arch A Pathol Anat Histopathol 418:27–32[CrossRef][Medline]
75. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, Heldin NE, Grimelius L 1996 EGF-receptors in human normal and pathological thyroid tissue. Histopathology 28:221–227[CrossRef][Medline]
76. Parlato R, Avantaggiato V, De Felice M 1999 TTF-1 and TTF-2 identify two different steps in thyroid morphogenesis. J Endocrinol Invest 22(Suppl):4 (Abstract)

This article has been cited by other articles:

				I. Cuesta, K. S. Zaret, and P. Santisteban The Forkhead Factor FoxE1 Binds to the Thyroperoxidase Promoter during Thyroid Cell Differentiation and Modifies Compacted Chromatin Structure Mol. Cell. Biol., October 15, 2007; 27(20): 7302 - 7314. [Abstract] [Full Text] [PDF]

				M. Milenkovic, X. De Deken, L. Jin, M. De Felice, R. Di Lauro, J. E Dumont, B. Corvilain, and F. Miot Duox expression and related H2O2 measurement in mouse thyroid: onset in embryonic development and regulation by TSH in adult J. Endocrinol., March 1, 2007; 192(3): 615 - 626. [Abstract] [Full Text] [PDF]

				N. Yeager, A. Klein-Szanto, S. Kimura, and A. Di Cristofano Pten Loss in the Mouse Thyroid Causes Goiter and Follicular Adenomas: Insights into Thyroid Function and Cowden Disease Pathogenesis Cancer Res., February 1, 2007; 67(3): 959 - 966. [Abstract] [Full Text] [PDF]

				Y. Sun, F. Zhang, J. Gao, X. Gao, T. Guo, K. Zhang, Y. Shi, Z. Zheng, W. Tang, Y. Zheng, et al. Positive association between POU1F1 and mental retardation in young females in the Chinese Han population Hum. Mol. Genet., April 1, 2006; 15(7): 1237 - 1243. [Abstract] [Full Text] [PDF]

				A. Venkateswaran, D. K. Marsee, S. H. Green, and S. M. Jhiang Forskolin, 8-Br-3',5'-Cyclic Adenosine 5'-Monophosphate, and Catalytic Protein Kinase A Expression in the Nucleus Increase Radioiodide Uptake and Sodium/Iodide Symporter Protein Levels in RET/PTC1-Expressing Cells J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6168 - 6172. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Felice, M. Articles by Di Lauro, R. Search for Related Content PubMed PubMed Citation Articles by De Felice, M. Articles by Di Lauro, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Medline Plus Health Information Thyroid Diseases